Time From First Intercourse to First Sexually Transmitted Infection Diagnosis Among Adolescent Women

Wanzhu Tu, PhD; Byron E. Batteiger, MD; Sarah Wiehe, MD, MPH; Susan Ofner, MS; Barbara Van Der Pol, PhD; Barry P. Katz, PhD; Donald P. Orr, MD; J. Dennis Fortenberry, MD, MS

Objective: To determine the time between first intercourse and first sexually transmitted infection (STI) with Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis and time between repeated infections.

Design: Observational study.

Setting: Three adolescent medicine clinics.

Participants: A cohort of 386 urban young women aged 14 to 17 years at enrollment.

Main Outcome Measures: Age at first intercourse; organism-specific interval between first intercourse and first STI diagnosis; interval between repeated infections; and age at first STI test prior to study participation.

Results: Participants had first intercourse at a young age (first, second, and third quartiles were 13, 14, and 15 years of age, respectively). By age 15 years, 25% of the women acquired their first STI, most often C. trachomatis. Median interval between first intercourse and first STI diagnosis was 2 years. Within 1 year of first intercourse, 25% had their first C. trachomatis infection. Repeated infections were common; within 3.6, 6, and 4.8 months, 25% of the women with prior C. trachomatis, N. gonorrhoeae, and T. vaginalis infection were reinfected with the respective organisms. Considerable delay in STI testing was found for those who began sex at a younger age. The median interval between first sex and first test were 4.9, 3.5, 2.1, 1.8, and 1.2 years for those who had first sex at ages 10, 11, 12, 13, and 14 years, respectively.

Conclusions: Timely screening and treatment are important for prevention of STI sequelae. For urban adolescent women, STI screening (especially for C. trachomatis) should begin within a year after first intercourse and infected individuals should be retested every 3 to 4 months.

Arch Pediatr Adolesc Med. 2009;163(12):1106-1111

Screening adolescent women for selected sexually transmitted infections (STIs)—by sexual history to identify risk and by laboratory testing to verify infection—is endorsed by clinical practice guidelines and implemented in at least some proportion of health visits for adolescents. Sexually transmitted infection screening is justified by disproportionate STI morbidity among young women, including pelvic inflammatory disease, ectopic pregnancy, tubal infertility, preterm birth, and increased susceptibility to human immunodeficiency virus infection. The 2006 Sexually Transmitted Diseases Treatment Guidelines recommend Chlamydia screening for women younger than 26 years but do not suggest a beginning age for such screening. Similarly, the US Preventive Services Task Force makes no recommendations about the beginning age of STI screening and periodicity of screening because of limitations of epidemiological data. These limitations include relatively short follow-up periods, infrequent testing schedules, and the inability to reliably ascertain infection outside the observational period and study venues. A clearly delineated timeline of major events related to STI acquisition in the life of young women would provide a basis for more effective STI screening strategies. Additionally, such data could shed new light on the natural history of STI during adolescence and young adulthood.

Herein, we used data from a longitudinal study in combination with participants' medical records. The combined data offered a unique opportunity to reconstruct infection histories in a group of inner-city young women. We addressed 3 questions about the timing of STI-related events. First, what is the interval between a young woman's first sexual intercourse and her first Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis infection? Answers to this question could better guide decisions about the appropriate timing of first STI screening. Second, what...
STUDY DESIGN

This analysis is based on a convenience sample of young women enrolled in a longitudinal study of factors related to STI, referred to as the Young Women’s Project (YWP). Enrollment started in 1999, with maximal length of follow-up approaching 8.2 years (2995 days). The research was approved by the institutional review board of Indiana University–Purdue University at Indianapolis.

Enrollment

Young women between the ages of 14 and 17 years, able to understand English, without serious psychiatric diagnoses or substance use disorder and attending 1 of 3 adolescent medicine clinics were eligible for enrollment. The 3 adolescent medicine clinics primarily served the inner-city population of Indianapolis. Young women were identified by clinic schedule and those who agreed to participate were enrolled at the current or subsequent clinical visit. Young women were enrolled without regard to sexual experience. Participants’ written informed consent and written parental permission were obtained at enrollment.

At enrollment, participants completed a self-administered questionnaire and a face-to-face interview with trained research associates to establish lifetime and recent (past 3 months) sexual behaviors, as well as lifetime STI history. Cervical and vaginal specimens were collected by a research nurse practitioner.

Follow-up

Participants returned for follow-up every 3 months. At each 3-month visit, participants completed face-to-face interviews to establish sexual behaviors in the previous 3 months. Participants had high completion rates for quarterly interviews, with only 5% of possible follow-up interviews missing. The self-administered questionnaire was repeated annually. Cervical and vaginal specimens were obtained for STI testing every 3 months. In alternating quarters, study participants were instructed to complete daily behavioral diaries and submit weekly self-administered vaginal swabs for STI testing. Self-administered vaginal swabs have shown high acceptability and excellent sensitivity and specificity. Vaginal swab samples were retrieved by study personnel each week. Samples were stored at −20°C and processed in batches and test results were made available to study personnel just before each participant’s subsequent quarterly visit, at which time infected participants were treated.

Study participants were compensated $2 for each completed diary and $5 for each cervicovaginal specimen.

ASCERTAINMENT OF DEMOGRAPHIC AND SEXUAL BEHAVIORAL INFORMATION

Demographic and sexual behavioral information was ascertained from the interviews and diaries. At each interview, participants were asked about lifetime and past 3 months’ experiences of vaginal, oral, and anal sex; lifetime and past 3 months’ sexual partners; and intercourse frequency and condom use in the past 3 months. Age at first sexual intercourse and lifetime history of STI were obtained at enrollment and annually.

STI TESTING AND DETERMINATION OF INFECTION EPISODES

Nucleic acid amplification tests (NAATs) were used to analyze all study specimens for C trachomatis and N gonorrhoeae (Amplicor CT/NG PCR; Roche Diagnostics, Indianapolis). Detection of T vaginalis DNA was performed using a modification of the Amplicor CT/NG PCR assay that included primers and probes specific for T vaginalis. The following decision rule was used to identify infections in this repetitively tested cohort. First, positive test results for C trachomatis, N gonorrhoeae, or T vaginalis obtained from participants’ medical records were considered as true infection episodes. Positive test results based on cervical swab samples conducted at quarterly clinical visits were also considered as true infection episodes, as consistent with current practice. In the absence of quarterly test results, we used weekly vaginal samples to determine the presence of C trachomatis or T vaginalis. For weekly samples, we required at least 3 positive NAAT results to avoid misinterpreting transient DNA deposited during recent coitus as new infection. We also required that these positive test results be at least 3 weeks after treatment of a previous infection to avoid misinterpreting transient DNA shedding following successful treatment as a new infection. Because of false-positive NAAT results for N gonorrhoeae, sampling tests positive by the Amplicor CT/NG PCR were confirmed by Gen-Probe (San Diego, California) Aptima, which amplifies a different molecular target.

DATA OBTAINED FROM PARTICIPANTS’ MEDICAL RECORDS

To reduce potential bias due to failure to identify sexual behavior and STI diagnosed before or outside of study participation, we examined the participants’ medical records for test results for C trachomatis, N gonorrhoeae, and T vaginalis. Medical records were searched with the aid of the Regenstrief Medical Record System (Regenstrief Institute, Inc, Indianapolis). The Regenstrief Medical Record System is a comprehensive electronic medical record system that links most major regional hospitals located in Indianapolis, including all primary care and acute care facilities affiliated with Wishard Health Services, to which the study sites belong. Additionally, we extracted and incorporated study participants’ test and treatment data from the county sexually transmitted disease clinic. Together, these clinics represent nearly all nonprivate STI testing facilities in the greater Indianapolis metropolitan area. Sexually transmitted infection testing methods were heterogeneous, including culture-based diagnostics (approximately 10% of diagnoses) and DNA amplification tests (about 90% of diagnoses) for C trachomatis and N gonorrhoeae. For T vaginalis, diagnoses were made by wet preparation microscopy (17%) and NAAT (83%). The high rates of NAAT diagnosis, especially for T vaginalis, reflected the fact that all research test results from the study laboratory, which were based on amplification meth-
Table 1. Demographic and Behavioral Characteristics of the Young Women’s Project Participants

<table>
<thead>
<tr>
<th>Subject Characteristic</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at enrollment, y (range, 14-17 y)</td>
<td>15.3 (1.1)</td>
</tr>
<tr>
<td>African American ethnicity, N. (%)</td>
<td>344 (89.1)</td>
</tr>
<tr>
<td>Length of follow-up, y (range, 0-8.2 y)</td>
<td>3.2 (2.0)</td>
</tr>
<tr>
<td>No. of partners in the last 2 mo, reported at enrollment</td>
<td>1 (1)</td>
</tr>
<tr>
<td>No. of partners during lifetime, reported at enrollment</td>
<td>3 (4) [2]</td>
</tr>
<tr>
<td>Age at first sexual intercourse, y^a</td>
<td>14.2 (2.0)</td>
</tr>
<tr>
<td>25th, 50th, 75th Percentiles</td>
<td>13, 14, 15</td>
</tr>
</tbody>
</table>

^aAge at first sex ascertained from interviews was accurate to the year.

DATA ANALYSIS

Demographic, behavioral, and clinical characteristics of study participants were summarized and reported in tabular form. First intercourse was the event of interest. Age at first intercourse was ascertained from the enrollment interview if the participant had been sexually active prior to study enrollment or from subsequent quarterly interviews or diaries if she had become sexually active during the study. Age at first sex for participants who had reported no intercourse either before or during the study was censored at the last study visit. The distribution of age at first sex was depicted by a Kaplan-Meier curve. We also used survival analyses to examine the time between the first sexual intercourse and the first diagnosis with C trachomatis, N gonorrhoeae, or T vaginalis infection. In this analysis, the events of interest were the first documented infections with each of the 3 organisms. The event times were censored at the last visit time if no infection was documented during the observation period. Selected quartiles (25th and 50th percentiles) of the event times were obtained and results reported in tabular form. Using similar techniques, we reported the interval from first to next infection as well as intervals between subsequent infections. Similarly, we examined the age distributions of the first infection with each of the 3 organisms.

Finally, we examined the timing of first STI test in relationship to the age at first intercourse. Because the test results obtained after study enrollment reflect study procedures instead of normal clinical STI testing behavior, we only used data from participants who had received STI tests as documented in their medical records prior to enrollment; participants who had received no STI tests before study participation were censored at enrollment. A scatterplot was used to present the relationship between the age at the first coitus and age at first STI test; different symbols were used to differentiate the observed non-study STI tests from the censored observations.

Baseline demographic, behavioral, and clinical characteristics of the 386 study participants measured at the time of enrollment are summarized in Table 1. Study participants reported an average of 3 partners in their lifetime (median, 2; range, 0-28) at enrollment. Three hundred sixty-four of the 386 participants (94%) reported first sexual intercourse prior to completing the study. Among the 364 sexually active women, 285 (78.3%) reported sexual intercourse prior to study enrollment and 79 (21.7%) became sexually active during the follow-up period. Age distribution of first sexual intercourse is shown in the Figure, A.

The average number of sexual partners in the 2 months prior to enrollment was 1 (median, 1; range, 0-10). Based on extracted medical record data, 147 (51.6%) of the 285 sexually experienced participants had 1 or more laboratory-documented C trachomatis (41.4%), N gonorrhoeae (14.0%), or T vaginalis (13.7%) infections prior to enrollment (Table 2). Self-reported STI history data were in agreement with the medical records. Of the 285 sexually experienced participants, 44% reported at least 1 STI prior to YWP enrollment; 37.2%, 15.8%, and 16.1% of these women reported prior C trachomatis, N gonorrhoeae, or T vaginalis infections.

The interval between first sexual intercourse and first STI diagnosis was examined by Kaplan-Meier estimates of the proportion of participants without C trachomatis, N gonorrhoeae, or T vaginalis infections. Table 2 shows that C trachomatis infections were identified significantly sooner than either N gonorrhoeae or T vaginalis infections. The median times between first sexual intercourse and first C trachomatis, N gonorrhoeae, or T vaginalis infections were 3, 5, and 6 years, respectively. A similar pattern was seen when time to first STI was examined as a function of chronicologic age. The median ages of the first C trachomatis, N gonorrhoeae, or T vaginalis infection were 17 years, 19 years, and 19 years, respectively. However, the median age of the first STI of any type was 16 years. The median length of infection-free interval following first sexual intercourse was only 2 years.

The intervals between the initial STI and first reinfection are shown in the Figure, C. Median time to first reinfection was 1.2 years (426 days). Median time to the first C trachomatis reinfection was about 1.6 years (581 days), with about 36% of these infections occurring in the first year. The median time to the first N gonorrhoeae reinfection was about 2.4 years (878 days), with 26% occurring in the first year following initial diagnosis of gonorrhea. Median time to the first T vaginalis reinfection was about 1.7 years (616 days). Within 2 years, about 75% of participants with an initial STI were diagnosed with a second STI, not necessarily of the same type. Within 4 years of an initial STI, virtually all (92%) of the participants had a second STI. When all repeated STIs were taken into account,
intervals between infections were even shorter (Table 2). The shorter intervals between later infections as opposed to first infections possibly reflect the increased frequency of testing during the study period compared with the pre-study period.

According to the extracted medical records, 283 of the 386 participants (73%) had received STI tests prior to YWP enrollment. The median age at first STI test received before YWP enrollment was 15 years (mean, 15.4 years), approximately 1 year after the median age of first sexual intercourse. Closer examination revealed that age at first STI test was not strongly correlated with the age at first sexual intercourse (Figure, D) (correlation coefficient=0.4). For women who had first sexual intercourse at younger ages (eg, at 10...
11, 12, 13, and 14 years), the median intervals between first sexual intercourse and first STI test were 4.9, 3.5, 2.1, 1.8, and 1.2 years, respectively.

**COMMENT**

Most women become sexually active during adolescence, and earlier age at first sexual intercourse is associated with increased STI risk. The US Preventive Services Task Force recommends screening women younger than 25 years for *C. trachomatis* and *N. gonorrhoeae*, and the Centers for Disease Control and Prevention suggests annual screening for *C. trachomatis* for sexually active women within 1 year of first coitus and screening for *N. gonorrhoeae* for women at increased risk until age 26 years. However, neither group has made evidence-based recommendations on the most appropriate starting age and the most appropriate frequency of screening.

To our knowledge, this research provides the first data on the timing of the initial and subsequent STIs following the onset of sexual activity in a high-risk sample of urban young women. Half of the study participants became infected within 2 years of first sexual intercourse, with *C. trachomatis* infection detected earlier than *N. gonorrhoeae* and *T. vaginalis* infections (P < .001). Repeated STIs were common, and the time to reinfections usually was very short, especially for *C. trachomatis*. This is consistent with the results of previous studies supporting relatively early rescreening following an initial STI, especially if the index infection is due to *C. trachomatis*. However, continuing surveillance may be necessary because of the continuing high risk of infection even if the first rescreening test result is negative.

The findings highlight the importance of early STI screening in urban adolescent women, especially considering the minimal harm of screening. For example, our data show that 25% of young women will have their first STI within 1 year after first intercourse (Table 2). Therefore, if screening starts within 1 year of first intercourse, a great majority (75%) of young women will have the benefit of screening before acquiring their first STI. Alternatively, our data can be used to support the beginning ages of screening in the absence of information about prior sexual activity. For example, 25% of first infections with *C. trachomatis*, *N. gonorrhoeae*, and *T. vaginalis* occur at ages 15, 17, and 17 years, respectively (Table 2). Therefore, beginning screening at age 15 years would bring benefit to more than 75% of the young women before acquiring the first infection. Similarly, our data can be used to guide screening frequency. If we wish to screen at a time when no more than 25% of reinfections have occurred with *C. trachomatis*, *N. gonorrhoeae*, and *T. vaginalis*, our screening intervals would be 3.6, 6, and 4.8 months, respectively (Table 2). If the 10th percentile is used, more aggressive screening for these organisms (in 2.4 months) would be needed. Similar rescreening intervals have been suggested for an urban adult population.

Despite the current guidelines’ dependence on clinical determination of sexual activity, the interval between first sexual intercourse and first STI test was especially prolonged for those with earliest onset of first intercourse. For example, the median delay of the first STI test was almost 5 years after the first coitus for those young women who reported first intercourse at age 10 years. A wide range of factors may have contributed to delayed screening, including vague language of the guidelines, patients’ deferral of appointments, and misperception among some providers that STI risk begins at later ages. Statutory requirement to report underage sexual activities may also discourage risk assessment. Regardless, these data are consistent with findings that physicians fail to obtain sexual history from a large proportion of adolescent patients. An important implication of these findings is the need for renewed emphasis on training, skills, and incentives to conduct such screenings by those who care for adolescent patients. Quality assurance standards such as the Health Plan Employer Data and Information Set (http://www.ncqa.org/tabid/892/Default.aspx) can serve as important reminders for screening for sexual activity among young women, although the Health Plan Employer Data and Information Set does not define sexual activity. Within the context of standards for preventive health care for young women, perhaps a more specific and achievable national health objective would be obtaining initial STI screening tests within 12 months of young women’s first sexual intercourse, as our data suggest.

Intervals between first sexual intercourse and first STI appear to be different for the 3 organisms, which to our knowledge, has not been prospectively demonstrated among adolescent women. This differential time to infection could at least in part be explained by the organisms’ respective prevalence rates among the partner population. Previous studies show that young age is associated with increased risk of *C. trachomatis* infection, while older age is associated with increased risk of *T. vaginalis* infections. Cervico-vaginal tissue immaturity, cervical ectopy, or immunologic naivete are proposed as explanations for age-related differences in *C. trachomatis* infections. However, the same ordering of STI was seen for each sexual intercourse onset cohort (data not shown). While the issue is beyond the scope of the current article, there may be a need for a closer examination of the transmission risks of these organisms. Whatever the explanation, these data lend more credence to current emphasis on early *C. trachomatis* screening among young women.

Our study focuses on a sample of urban adolescents at elevated STI risk, characterized by early age at first coitus, multiple sexual partners, and high STI rates. The results may not be readily generalizable to suburban and rural youths or urban residents of higher socioeconomic status. However, considering that inner-city residents of lower socioeconomic status bear much of the disease burden of STI, such a focus is justified. The research points to the need for future studies to examine the STI time patterns in other groups. Second, the use of STI tests obtained from electronic medical records raises the possibility that some tests were obtained for diagnostic evaluations rather than for routine screening. To the extent that this is true, it would lead to an underestimate of the STI incidence before the study period. Therefore, the actual occurrence of the first STI events following the onset of sex could be sooner than what we reported, thus justifying an even earlier starting age of screening. In this sense, our data represent a potentially more conservative timeline of STI testing events in adolescent women.

Timely screening and treatment of STIs in women, particularly *C. trachomatis*, decrease the risk of complications resulting from untreated infection. To achieve such a goal, STI screening should begin within a year after first inter-
course. Furthermore, because of ongoing high risk for subsequent infection, our study suggests the need for follow-up screening as frequently as every 3 to 4 months. We recognize the many financial and practical barriers to such intensive programs. Nevertheless, screening and treatment efforts based on evidence-based estimates of onset and level of risk will be the mainstay of prevention of STI complications.

Accepted for Publication: May 13, 2009.

Correspondence: Wanzhu Tu, PhD, Department of Medicine, Indiana University School of Medicine, 410 W 10th St, Ste 3000, Indianapolis, IN 46202 (wtu1@iupui.edu).

Author Contributions: Drs Fortenberry and Tu had full access to the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Tu, Batteiger, Wiehe, Katz, Orr, and Fortenberry. Acquisition of data: Batteiger, Van Der Pol, Orr, and Fortenberry. Analysis and interpretation of data: Tu, Batteiger, Wiehe, Ofner, Katz, Orr, and Fortenberry.

Drafting of the manuscript: Tu, Ofner, Katz, and Fortenberry. Critical revision of the manuscript for important intellectual content: Tu, Batteiger, Wiehe, Van Der Pol, Katz, Orr, and Fortenberry. Statistical analysis: Tu, Ofner, and Katz.

Obtained funding: Tu, Batteiger, Orr, and Fortenberry

Administrative, technical, and material support: Van Der Pol, Orr, and Fortenberry.

Study supervision: Fortenberry.

Financial Disclosure: Dr Van Der Pol has a consulting relationship with Roche Diagnostic Corporation.

Funding/Support: This work was supported by grants R01 HD042404, HD044387, and U19 AI031494-14 from the National Institutes of Health.

Role of the Sponsor: The sponsors provided financial support for the study only and had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the study; or in the preparation, review, or approval of the manuscript.

Additional Contributions: Stanley Taylor, MA, and Jane Wang, PhD, assisted with data management. We thank Stanley Spinola, MD, for comments on the manuscript.

REFERENCES


©2009 American Medical Association. All rights reserved.